| 000 | 01634 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515204226.0 | ||
| 264 | 0 | _c20110331 | |
| 008 | 201103s 0 0 eng d | ||
| 022 | _a1399-0012 | ||
| 024 | 7 |
_a10.1111/j.1399-0012.2009.01205.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aManuel, Oriol | |
| 245 | 0 | 0 |
_aGanciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. _h[electronic resource] |
| 260 |
_bClinical transplantation _c |
||
| 300 |
_a794-800 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCytomegalovirus _xdrug effects |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xprevention & control |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGanciclovir _xadministration & dosage |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKidney Transplantation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTissue Distribution |
| 650 | 0 | 4 | _aValganciclovir |
| 700 | 1 | _aPascual, Manuel | |
| 700 | 1 | _aPerrottet, Nancy | |
| 700 | 1 | _aLamoth, Frédéric | |
| 700 | 1 | _aVenetz, Jean-P | |
| 700 | 1 | _aDecosterd, Laurent A | |
| 700 | 1 | _aBuclin, Thierry | |
| 700 | 1 | _aMeylan, Pascal R | |
| 773 | 0 |
_tClinical transplantation _gvol. 24 _gno. 6 _gp. 794-800 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1399-0012.2009.01205.x _zAvailable from publisher's website |
| 999 |
_c19481134 _d19481134 |
||